LEVEL 4 N01AX07

Δραστικές

ETOMIDATE

Φάρμακα

  • DRUGBANK - Etomidate
  • indication:

    Used in the induction of general anesthesia.

  • pharmacology:

  • mechanism:

    Etomidate binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

  • toxicity:

    Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.

  • absorprion:

  • halflife:

    75 minutes.

  • roouteelimination:

    Approximately 75% of the administered dose is excreted in the urine during the first day after injection.

  • volumedistribution:

  • clearance: